Federated Investors Inc. PA cut its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 17.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 58,326 shares of the medical equipment provider’s stock after selling 11,969 shares during the period. Federated Investors Inc. PA owned about 0.16% of Lantheus Holdings worth $1,029,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Trexquant Investment LP bought a new stake in shares of Lantheus Holdings in the 1st quarter worth about $332,000. Systematic Financial Management LP bought a new stake in shares of Lantheus Holdings in the 1st quarter worth about $1,314,000. Nordea Investment Management AB increased its holdings in shares of Lantheus Holdings by 23.7% in the 1st quarter. Nordea Investment Management AB now owns 127,700 shares of the medical equipment provider’s stock worth $1,596,000 after buying an additional 24,500 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Lantheus Holdings by 6.3% in the 1st quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock worth $856,000 after buying an additional 4,084 shares during the last quarter. Finally, FNY Partners Fund LP bought a new stake in shares of Lantheus Holdings in the 1st quarter worth about $174,000. Hedge funds and other institutional investors own 84.35% of the company’s stock.
In other Lantheus Holdings news, CEO Mary Anne Heino sold 10,000 shares of Lantheus Holdings stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $18.05, for a total transaction of $180,500.00. Following the transaction, the chief executive officer now directly owns 592,468 shares of the company’s stock, valued at $10,694,047.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David F. Burgstahler sold 3,000,000 shares of Lantheus Holdings stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $14.87, for a total transaction of $44,610,000.00. The disclosure for this sale can be found here. Insiders have sold 3,906,344 shares of company stock worth $60,109,626 over the last ninety days. 2.30% of the stock is owned by insiders.
Lantheus Holdings, Inc. (LNTH) opened at 17.15 on Friday. Lantheus Holdings, Inc. has a one year low of $7.61 and a one year high of $17.65. The company’s 50-day moving average is $17.18 and its 200 day moving average is $15.49. The company has a market capitalization of $640.55 million, a P/E ratio of 23.43 and a beta of 0.94.
Lantheus Holdings (NASDAQ:LNTH) last posted its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.18. Lantheus Holdings had a net margin of 8.44% and a negative return on equity of 37.47%. The firm had revenue of $88.83 million for the quarter, compared to the consensus estimate of $80.56 million. During the same period last year, the firm posted $0.24 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post $1.12 earnings per share for the current year.
A number of analysts have recently weighed in on the stock. BidaskClub downgraded shares of Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 17th. Zacks Investment Research upgraded shares of Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $18.00 target price on the stock in a report on Thursday, August 3rd. Cantor Fitzgerald assumed coverage on shares of Lantheus Holdings in a report on Monday, July 17th. They issued an “overweight” rating and a $22.00 target price on the stock. Jefferies Group LLC restated a “buy” rating and issued a $18.00 target price on shares of Lantheus Holdings in a report on Friday, June 30th. Finally, Credit Suisse Group boosted their target price on shares of Lantheus Holdings from $14.00 to $19.00 and gave the stock a “neutral” rating in a report on Wednesday, August 2nd. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $18.60.
TRADEMARK VIOLATION NOTICE: This news story was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/16/federated-investors-inc-pa-trims-stake-in-lantheus-holdings-inc-lnth.html.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.